| 33.25 1.31 (4.1%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 41.98 |
1-year : | 49.04 |
| Resists | First : | 35.95 |
Second : | 41.98 |
| Pivot price | 33.28  |
|||
| Supports | First : | 31.38 |
Second : | 28.56 |
| MAs | MA(5) : | 31.72 |
MA(20) : | 33.39 |
| MA(100) : | 31.18 |
MA(250) : | 36.77 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 45.7 |
D(3) : | 38.7 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 50.47 | Low : | 25.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RARE ] has closed above bottom band by 49.3%. Bollinger Bands are 5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.33 - 33.49 | 33.49 - 33.63 |
| Low: | 31.12 - 31.3 | 31.3 - 31.46 |
| Close: | 32.94 - 33.25 | 33.25 - 33.53 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Tue, 11 Nov 2025
Ultragenyx gets $400 million cash infusion, reports 15% rise in sales - The Press Democrat
Tue, 11 Nov 2025
Fox Run Management L.L.C. Invests $607,000 in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Mon, 10 Nov 2025
Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT - Insider Monkey
Sat, 08 Nov 2025
Ultragenyx Pharmaceutical (RARE): Exploring Valuation Gaps and Analyst Targets - Sahm
Sat, 08 Nov 2025
Ultragenyx Pharmaceutical (RARE): Exploring Valuation Gaps and Analyst Targets - simplywall.st
Thu, 06 Nov 2025
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $75.00 at TD Cowen - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 96 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 100.8 (%) |
| Shares Short | 8,690 (K) |
| Shares Short P.Month | 7,950 (K) |
| EPS | -5.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.57 |
| Profit Margin | -87.4 % |
| Operating Margin | -64.9 % |
| Return on Assets (ttm) | -21.6 % |
| Return on Equity (ttm) | -180.5 % |
| Qtrly Rev. Growth | 13.1 % |
| Gross Profit (p.s.) | -1.75 |
| Sales Per Share | 6.33 |
| EBITDA (p.s.) | -4.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -421 (M) |
| Levered Free Cash Flow | -206 (M) |
| PE Ratio | -6.07 |
| PEG Ratio | 0 |
| Price to Book value | 21.17 |
| Price to Sales | 5.25 |
| Price to Cash Flow | -7.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|